Results 41 to 50 of about 420 (147)

Contezolid for the Treatment of Drug-Resistant Tuberculosis in China: A Clinical Case Series

Infection and Drug Resistance
Yan-Jun Xiong,* Yu Xiao,* Lei Xie, Lei Gao, Yi Han, Peng-Fei Huang, Shuang Liu, Ya-Xue Liang, Hua Wang Department of Tuberculosis, Anhui Provincial Chest Hospital (Anhui Institute of Tuberculosis Control), Hefei, Anhui, 230022, People’s Republic ...
Xiong YJ, Xiao Y, Xie L, Gao L, Han Y, Huang PF, Liu S, Liang YX, Wang H   +8 more
doaj   +3 more sources

Contezolid: First Approval [PDF]

Drugs, 2021
Contezolid (Youxitai ®), an orally administered oxazolidinone antibacterial agent, is being developed by Shanghai MicuRx Pharmaceutical Co., Ltd. for the treatment of multidrug-resistant (MDR) Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci.
openaire   +2 more sources

1700. Efficacy and Safety in Subjects with Renal Impairment in Contezolid and Contezolid Acefosamil Phase 2 and Phase 3 Skin Infection Clinical Trials

Open Forum Infectious Diseases, 2022
Abstract Background Contezolid (CZD; MRX-I) is a novel oral (PO) oxazolidinone with potent activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enteroccocus (VRE).
Fang, Edward, Yang, Huahui, Yuan, Hong
openaire   +2 more sources

Strategies to Improve the Potency of Oxazolidinones towards Bacterial Biofilms

Chemistry – An Asian Journal, Volume 17, Issue 11, June 1, 2022., 2022
Biofilms play a key role in chronic infections yet they are highly resistant to antibiotic treatment. One approach to develop new anti‐biofilm agents is to modify the structure of existing antibiotics to target biofilms. In this review, we provide insight into strategies used to design more potent oxazolidinone compounds with activity against bacterial
Audrey R. N. Ndukwe, Sandra Wiedbrauk, Nathan R. B. Boase, Kathryn E. Fairfull‐Smith   +3 more
wiley   +1 more source

Advances in Key Drug Target Identification and New Drug Development for Tuberculosis

BioMed Research International, Volume 2022, Issue 1, 2022., 2022
Tuberculosis (TB) is a severe infectious disease worldwide. The increasing emergence of drug‐resistant Mycobacterium tuberculosis (Mtb) has markedly hampered TB control. Therefore, there is an urgent need to develop new anti‐TB drugs to treat drug‐resistant TB and shorten the standard therapy.
Jie Mi, Wenping Gong, Xueqiong Wu, Atef M. Al Attar   +3 more
wiley   +1 more source

Regulatory utility of pharmacometrics in the development and evaluation of antimicrobial agents and its recent progress in China

CPT: Pharmacometrics &Systems Pharmacology, Volume 10, Issue 12, Page 1466-1478, December 2021., 2021
Abstract Pharmacometrics is an emerging science that interprets drug, disease, and trial information in a mathematical fashion to inform and facilitate efficient drug development and/or regulatory decisions. Pharmacometrics study is increasingly adopted in the regulatory review of new antimicrobial agents.
Ming Zhao, Yuancheng Chen, Dong Yang, Cheng Lyu, Xingchen Bian, Xin Li, Weiyi Qiu, Zhiwei Huang, Zijian Hu, Jing Zhang   +9 more
wiley   +1 more source

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China

Frontiers in Medicine, 2022
ObjectiveTo investigate the in vitro activities of five oxazolidinones in parallel against the reference strains of different mycobacterial species and clinical isolates of Mycobacterium tuberculosis (Mtb), and shed light on the differences in the ...
Chenqian Wang, Chenqian Wang, Guirong Wang, Fengmin Huo, Yi Xue, Junnan Jia, Lingling Dong, Liping Zhao, Fen Wang, Hairong Huang, Hongfei Duan   +10 more
doaj   +1 more source

A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro

Antimicrobial Agents and Chemotherapy, 2021
An evaluation of the anti- Mycobacterium abscessus activity expressed by a novel oxazolidinone, contezolid (MRX-I), toward 12 reference strains and 194 clinical isolates was conducted. Contezolid was active against M. abscessus in vitro , with effects comparable to the anti-
Qi Guo, Liyun Xu, Fusheng Tan, Yongjie Zhang, Junsheng Fan, Xinghai Wang, Zhemin Zhang, Bing Li, Haiqing Chu   +8 more
openaire   +2 more sources

Drug Repurposing for Tuberculosis [PDF]

, 2021
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a major global health concern given the increase in multiple forms of drug-resistant TB. This underscores the importance of a continuous pipeline of new anti-TB agents.
Cardoso, Nicole C., Oosthuizen, Carel B., Peton, Nashied, Singh, Vinayak   +3 more
core   +2 more sources

Antibacterial activity of the novel compound Sudapyridine (WX-081) against Mycobacterium abscessus [PDF]

, 2023
ObjectiveThis study aimed to investigate sudapyridine (WX-081) antibacterial activity against Mycobacterium abscessus in vitro and its effect on in vivo bacterial growth and host survival using a zebrafish model of M. abscessus infection.MethodsWX-081 in
Lei Su, Lina Liu, Naihui Chu, Naihui Chu, Ruixue Geng, Shan Gao, Shan Gao, Wenjuan Nie, Wenjuan Nie, Yingxia You   +9 more
core   +1 more source